Indian pharma under pressure! 💊📉

Lupin (-1.76%) and Dr. Reddy’s (-1.53%) slipped as US President Trump announced a 100% tariff on branded & patented drug exports. While Indian players mainly sell generics, the US remains their largest export market—35% of $10B in FY25. This raises fresh concerns for margins, pricing power, and long-term competitiveness of Indian pharma abroad. Traders are bracing for volatility, while investors look for clarity: Will generics remain shielded, or is this just the beginning of tougher US trade policies?